Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 studyThe Lancet Oncology - Tập 12 - Trang 361-368 - 2011
Stephen M Ansell, Hui Tang, Paul J Kurtin, Patricia A Koenig, David J Inwards, Keith Shah, Steven C Ziesmer, Andrew L Feldman, Radha Rao, Mamta Gupta, Charles Erlichman, Thomas E Witzig
Validity of Adjuvant! Online program in older patients with breast cancer: a population-based studyThe Lancet Oncology - Tập 15 - Trang 722-729 - 2014
Nienke A de Glas, Willemien van de Water, Ellen G Engelhardt, Esther Bastiaannet, Anton J M de Craen, Judith R Kroep, Hein Putter, Anne M Stiggelbout, Nir I Weijl, Cornelis J H van de Velde, Johanneke E A Portielje, Gerrit-Jan Liefers
Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient dataThe Lancet Oncology - Tập 11 - Trang 835-844 - 2010
Monique Maas, Patty J Nelemans, Vincenzo Valentini, Prajnan Das, Claus Rödel, Li-Jen Kuo, Felipe A Calvo, Julio García-Aguilar, Rob Glynne-Jones, Karin Haustermans, Mohammed Mohiuddin, Salvatore Pucciarelli, William Small, Javier Suárez, George Theodoropoulos, Sebastiano Biondo, Regina GH Beets-Tan, Geerard L Beets
Meningiomas in children and adolescents: a meta-analysis of individual patient dataThe Lancet Oncology - Tập 12 - Trang 1229-1239 - 2011
Rishi S Kotecha, Elaine M Pascoe, Elisabeth J Rushing, Lucy B Rorke-Adams, Ted Zwerdling, Xing Gao, Xin Li, Stephanie Greene, Abbas Amirjamshidi, Seung-Ki Kim, Marco A Lima, Po-Cheng Hung, Fayçal Lakhdar, Nirav Mehta, Yuguang Liu, B Indira Devi, B Jayanand Sudhir, Morten Lund-Johansen, Flemming Gjerris, Catherine H Cole
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trialThe Lancet Oncology - Tập 19 - Trang 1617 - 2018
Pearson Andrew D J, Chan Godfrey Chi Fung, Brock Penelope, Holmes Keith, Castellani Maria Rita, Ambros Peter, Yaniv Isaac, Beck Popovic Maja, Gaze Mark N, Lode Holger N, Loibner Hans, Schreier Guenter, Schroeder Henrik, Luksch Roberto, Garaventa Alberto, Owens Cormac, Laureys Genevieve, Trahair Toby, Michon Jean Marie, Castel Victoria, Ladenstein Ruth, Ruud Ellen, Pötschger Ulrike, Valteau-Couanet Dominique
Background Immunotherapy with the chimeric anti-GD2 monoclonal antibody dinutuximab, combined with alternating granulocyte-macrophage colony-stimulating factor and intravenous interleukin-2 (IL-2), improves survival in patients with high-risk neuroblastoma. We aimed to assess event-free survival after treatment with ch14.18/CHO (dinutuximab beta) and subcutaneous IL-2, compared with dinutuximab be...... hiện toàn bộ
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trialThe Lancet Oncology - Tập 17 - Trang 1374-1385 - 2016
Howard L Kaufman, Jeffery Russell, Omid Hamid, Shailender Bhatia, Patrick Terheyden, Sandra P D'Angelo, Kent C Shih, Céleste Lebbé, Gerald P Linette, Michele Milella, Isaac Brownell, Karl D Lewis, Jochen H Lorch, Kevin Chin, Lisa Mahnke, Anja von Heydebreck, Jean-Marie Cuillerot, Paul Nghiem